Cetera Investment Advisers Crispr Therapeutics Ag Transaction History

Cetera Investment Advisers

  • $80.6 Billion
  • Q3 2025

A detailed history of Cetera Investment Advisers transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Cetera Investment Advisers holds 63,830 shares of CRSP stock, worth $3.53 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
63,830
Previous 48,015 32.94%
Holding current value
$3.53 Million
Previous $2.34 Million 77.13%
% of portfolio
0.01%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
BUY
$48.51 - $68.14 $767,185 - $1.08 Million
15,815 Added 32.94%
63,830 $4.14 Million
Q2 2025

Aug 08, 2025
SELL
$31.27 - $48.64 $309,698 - $481,730
-9,904 Reduced 17.1%
48,015 $2.34 Million
Q1 2025

May 06, 2025
BUY
$34.03 - $53.02 $955,698 - $1.49 Million
28,084 Added 94.13%
57,919 $1.97 Million
Q4 2024

Feb 13, 2025
SELL
$38.65 - $55.15 $223,281 - $318,601
-5,777 Reduced 16.22%
29,835 $1.17 Million
Q3 2024

Nov 13, 2024
BUY
$44.62 - $62.75 $391,495 - $550,568
8,774 Added 32.69%
35,612 $1.67 Million
Q2 2024

Aug 22, 2024
SELL
$51.17 - $68.18 $371,596 - $495,123
-7,262 Reduced 21.3%
26,838 $1.45 Million
Q1 2024

May 24, 2024
BUY
$60.67 - $89.12 $1.64 Million - $2.42 Million
27,109 Added 387.77%
34,100 $2.32 Million
Q1 2024

May 14, 2024
BUY
$60.67 - $89.12 $48,900 - $71,830
806 Added 13.03%
6,991 $476,000
Q4 2023

Feb 13, 2024
BUY
$38.62 - $72.18 $16,992 - $31,759
440 Added 7.66%
6,185 $387,000
Q3 2023

Nov 14, 2023
BUY
$45.39 - $59.0 $1,724 - $2,242
38 Added 0.67%
5,745 $260,000
Q2 2023

Aug 09, 2023
SELL
$43.47 - $67.77 $109,500 - $170,712
-2,519 Reduced 30.62%
5,707 $320,000
Q1 2023

May 15, 2023
SELL
$41.0 - $56.12 $15,334 - $20,988
-374 Reduced 4.35%
8,226 $372,000
Q4 2022

Feb 14, 2023
BUY
$39.19 - $65.67 $76,694 - $128,516
1,957 Added 29.46%
8,600 $349,000
Q3 2022

Nov 10, 2022
SELL
$61.1 - $83.78 $86,823 - $119,051
-1,421 Reduced 17.62%
6,643 $434,000
Q2 2022

Aug 11, 2022
BUY
$43.23 - $73.83 $10,245 - $17,497
237 Added 3.03%
8,064 $490,000
Q1 2022

May 13, 2022
BUY
$53.19 - $79.24 $45,902 - $68,384
863 Added 12.39%
7,827 $491,000
Q4 2021

Feb 14, 2022
SELL
$70.09 - $111.29 $17,732 - $28,156
-253 Reduced 3.51%
6,964 $528,000
Q3 2021

Nov 16, 2021
BUY
$110.2 - $156.64 $89,151 - $126,721
809 Added 12.62%
7,217 $808,000
Q2 2021

Aug 13, 2021
BUY
$100.84 - $161.89 $180,100 - $289,135
1,786 Added 38.64%
6,408 $1.04 Million
Q1 2021

May 17, 2021
SELL
$110.72 - $210.04 $54,142 - $102,709
-489 Reduced 9.57%
4,622 $563,000
Q4 2020

Feb 17, 2021
BUY
$79.67 - $173.23 $407,193 - $885,378
5,111 New
5,111 $783,000

Others Institutions Holding CRSP

# of Institutions
548
Shares Held
67.7M
Call Options Held
3.5M
Put Options Held
3.08M
View Full List

About CRISPR Therapeutics AG

CRSP Quotes by TradingView
  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.32B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email